Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BT0Z
|
|||
| Former ID |
DIB002076
|
|||
| Drug Name |
PF-05241328
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Phase 1 | [1] | |
| Company |
Pfizer Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H21ClN4O4S
|
|||
| Canonical SMILES |
CC1=NN(C2=C1C=C(C=C2)C(=O)NS(=O)(=O)C)C3=CC(=C(N=C3)OCC(C)C)Cl
|
|||
| InChI |
1S/C19H21ClN4O4S/c1-11(2)10-28-19-16(20)8-14(9-21-19)24-17-6-5-13(7-15(17)12(3)22-24)18(25)23-29(4,26)27/h5-9,11H,10H2,1-4H3,(H,23,25)
|
|||
| InChIKey |
RVTSXVZXEGFIPW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1387633-03-5
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Voltage-gated sodium channel alpha Nav1.7 (SCN9A) | Target Info | Inhibitor | [2] |
| Reactome | Interaction between L1 and Ankyrins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01165736) To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity. U.S. National Institutes of Health. | |||
| REF 2 | Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.